Innovation in
Intrabody
Development.

ProCodeTM is the only platform that selects Intrabodies based on their solubility, expression and function in the cellular cytoplasm. Intrabodies can target protein-protein interactions, phosphorylation and other novel interactions in cytoplasmic signaling pathways using dose and affinity to demonstrate pharmacologically relevant events. Intrabodies can validate drug targets and function as drugs to treat a wide range of diseases such as cancer, chronic and acute inflammatory disease, infectious disease and autoimmune disease.

LATEST NEWS:

March 28, 2012
PharmCode for Precision in Target Validation More»

September 28, 2011
Vybion has been notified by the US Patent office of the issue of Patent No. 8,029,985 on October 4, 2011 entitled "Amplified Bioassay". More»

November 1, 2010
Vybion was awarded $244,000 through the Qualifying Therapeutic Discovery Project (QTDP) for ProCode development of therapeutic products. More»

October 25, 2010
Vybion announces an Alliance with Meridian Life Sciences for ProCode applications to the Biomarker and Diagnostic Industry. More»

October 20, 2010
Vybion and ALS Biopharma announce a Strategic Alliance based on Vybion NPEG technology More»

December 3, 2009
Vybion receives grant award from NIH for “Rapid Isolation of High Affinity Human Antibodies from Large Synthetic Libraries”. More»

November 1, 2009
Lee Henderson, Ph.D. was invited to give a presentation at the PepCon Conference in Beijing, China in late March. More»

July 2009
Vybion file patent for novel pegylation technology to improve and fine tune the pharmacokinetic properties of biologics. More»

Jun 10, 2009
Ithaca, NY: Vybion has received a $1.3M subcontract on at $7.1M NIH Cooperative Agreement to develop diagnostics for Lassa Virus, a deadly hemorrhagic virus endemic in West Africa. More»


			        $('#s6').cycle({
			    	fx:     'scrollUp',
			    	timeout: 6000,
			    	delay:  -2000
					});

  • Selection in days/entire panel programs in weeks
  • Intrabody selection
  • Traditional antibodies
  • Higher stability and solubility
  • Fragment, single chain to full length